Organogenesis Holdings Lowers FY2026 Sales Guidance from $350.000M-$420.000M to $270.000M-$310.000M vs $401.200M Est
Benzinga Newsdesk 6 months ago
NewsGuidance
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $350.000 million-$420.000 million to $270.000 million-$310.000 million vs $401.200 million estimate.
Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $350.000 million-$420.000 million to $270.000 million-$310.000 million vs $401.200 million estimate.